4.6 Review

Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review

Journal

PHARMACEUTICALS
Volume 15, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/ph15060764

Keywords

autosomal recessive cerebellar ataxia; rare neurodegenerative disease; genetic mutation; preclinical model; oxidative stress; antioxidant pathway and therapy

Funding

  1. University of Malaya Faculty of Medicine Research Grant [GPF003C-2019]
  2. Universiti Malaya Faculty of Medicine's Postgraduate Scholarship Fund [UM.0000092/KWD.BH]

Ask authors/readers for more resources

This systematic review evaluates the current developments in therapeutic strategies targeting oxidative stress for the management of autosomal recessive cerebellar ataxias (ARCAs). The review finds that antioxidant therapies show promise in improving or halting the progression of the disease. Tailoring the therapies to specific disease stages could greatly facilitate disease management.
Autosomal recessive cerebellar ataxias (ARCAs) are a heterogeneous group of rare neurodegenerative inherited disorders. The resulting motor incoordination and progressive functional disabilities lead to reduced lifespan. There is currently no cure for ARCAs, likely attributed to the lack of understanding of the multifaceted roles of antioxidant defense and the underlying mechanisms. This systematic review aims to evaluate the extant literature on the current developments of therapeutic strategies that target oxidative stress for the management of ARCAs. We searched PubMed, Web of Science, and Science Direct Scopus for relevant peer-reviewed articles published from 1 January 2016 onwards. A total of 28 preclinical studies fulfilled the eligibility criteria for inclusion in this systematic review. We first evaluated the altered cellular processes, abnormal signaling cascades, and disrupted protein quality control underlying the pathogenesis of ARCA. We then examined the current potential therapeutic strategies for ARCAs, including aromatic, organic and pharmacological compounds, gene therapy, natural products, and nanotechnology, as well as their associated antioxidant pathways and modes of action. We then discussed their potential as antioxidant therapeutics for ARCAs, with the long-term view toward their possible translation to clinical practice. In conclusion, our current understanding is that these antioxidant therapies show promise in improving or halting the progression of ARCAs. Tailoring the therapies to specific disease stages could greatly facilitate the management of ARCAs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available